511 related articles for article (PubMed ID: 10403901)
1. Nm-23, c-erbB-2, and progesterone receptor expression in invasive breast cancer: correlation with clinicopathologic parameters.
Nakopoulou LL; Tsitsimelis D; Lazaris AC; Tzonou A; Gakiopoulou H; Dicoglou CC; Davaris PS
Cancer Detect Prev; 1999; 23(4):297-308. PubMed ID: 10403901
[TBL] [Abstract][Full Text] [Related]
2. Expression of metastasis-associated genes h-mts1 (S100A4) and nm23 in carcinoma of breast is related to disease progression.
Albertazzi E; Cajone F; Leone BE; Naguib RN; Lakshmi MS; Sherbet GV
DNA Cell Biol; 1998 Apr; 17(4):335-42. PubMed ID: 9570150
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous expression of nm23 gene product as a predictor of lymph nodal status in human breast cancer.
Yoshida H; Kijima H; Terasaki Y; Suto A; Takeshita T; Omiya H; Shimojima K; Shimbori M; Sato T; Sato S; Onoda N; Yamazaki H; Tamaoki N; Ueyama Y; Nakamura M
Int J Oncol; 1998 Dec; 13(6):1141-6. PubMed ID: 9824622
[TBL] [Abstract][Full Text] [Related]
4. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
5. Nm23 gene product expression in invasive breast cancer--immunohistochemical analysis and clinicopathological correlation.
Belev B; Alerić I; Vrbanec D; Petrovecki M; Unusic J; Jakić-Razumović J
Acta Oncol; 2002; 41(4):355-61. PubMed ID: 12234027
[TBL] [Abstract][Full Text] [Related]
6. Expression of NM23 and tenascin in invasive ductal carcinomas of the breast.
Kaya H; Hücümenoğlu S; Bozkurt SU; Ekicioğlu G; Kotiloğlu E
Eur J Gynaecol Oncol; 2002; 23(3):261-3. PubMed ID: 12094967
[TBL] [Abstract][Full Text] [Related]
7. NM23 gene expression in human breast carcinomas: loss of correlation with cell proliferation in the advanced phase of tumor progression.
Caligo MA; Cipollini G; Berti A; Viacava P; Collecchi P; Bevilacqua G
Int J Cancer; 1997 Feb; 74(1):102-11. PubMed ID: 9036878
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous expression of nm23 gene product in noninvasive breast carcinoma.
Simpson JF; O'Malley F; Dupont WD; Page DL
Cancer; 1994 May; 73(9):2352-8. PubMed ID: 7513249
[TBL] [Abstract][Full Text] [Related]
9. Expression patterns of ER, HER2, and NM23-H1 in breast cancer patients with different menopausal status: correlations with metastasis.
Dong SW; Wang L; Sui J; Deng XY; Chen XD; Zhang ZW; Liu X; Liu ZM; Zhang JH; Yang QS; Jia YF; Song X
Mol Diagn Ther; 2011 Aug; 15(4):211-9. PubMed ID: 21913743
[TBL] [Abstract][Full Text] [Related]
10. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation.
Bertheau P; Steinberg SM; Merino MJ
Hum Pathol; 1998 Apr; 29(4):323-9. PubMed ID: 9563780
[TBL] [Abstract][Full Text] [Related]
11. Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix.
Mandai M; Konishi I; Koshiyama M; Komatsu T; Yamamoto S; Nanbu K; Mori T; Fukumoto M
Cancer; 1995 May; 75(10):2523-9. PubMed ID: 7736397
[TBL] [Abstract][Full Text] [Related]
12. nm23--relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients.
Russell RL; Geisinger KR; Mehta RR; White WL; Shelton B; Kute TE
Cancer; 1997 Mar; 79(6):1158-65. PubMed ID: 9070493
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancer.
Tokunaga Y; Urano T; Furukawa K; Kondo H; Kanematsu T; Shiku H
Int J Cancer; 1993 Aug; 55(1):66-71. PubMed ID: 8102131
[TBL] [Abstract][Full Text] [Related]
14. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the expression levels of nm23-H1 mRNA in primary breast cancer, benign breast disease, axillary lymph nodes and normal breast tissue.
Goodall RJ; Dawkins HJ; Robbins PD; Hähnel E; Sarna M; Hähnel R; Papadimitriou JM; Harvey JM; Sterrett GF
Pathology; 1994 Oct; 26(4):423-8. PubMed ID: 7892043
[TBL] [Abstract][Full Text] [Related]
16. Correlation of nm23-H1 gene expression with clinical outcome in patients with advanced breast cancer.
Sgouros J; Galani E; Gonos E; Moutsatsou P; Belechri M; Skarlos D; Dionyssiou-Asteriou A
In Vivo; 2007; 21(3):519-22. PubMed ID: 17591363
[TBL] [Abstract][Full Text] [Related]
17. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.
Heimann R; Lan F; McBride R; Hellman S
Cancer Res; 2000 Jan; 60(2):298-304. PubMed ID: 10667580
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
Sirotkovic-Skerlev M; Krizanac S; Kapitanovic S; Husnjak K; Unusic J; Pavelic K
Exp Mol Pathol; 2005 Aug; 79(1):42-50. PubMed ID: 16005711
[TBL] [Abstract][Full Text] [Related]
19. Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis.
Müller W; Schneiders A; Hommel G; Gabbert HE
Cancer; 1998 Dec; 83(12):2481-7. PubMed ID: 9874452
[TBL] [Abstract][Full Text] [Related]
20. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition.
Hartsough MT; Clare SE; Mair M; Elkahloun AG; Sgroi D; Osborne CK; Clark G; Steeg PS
Cancer Res; 2001 Mar; 61(5):2320-7. PubMed ID: 11280805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
